GlassScriptPhysician profile
Elise Ballard
NPI 1275385361
$10,002.04
in general payments reported to CMS, 2019-2025
18 companies · $4,613 in 2025
The $4,613 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,389 · 2025: $4,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,019 · Food and Beverage: $2,950 · Travel and Lodging: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,019.21 |
| Food and Beverage | $2,949.50 |
| Travel and Lodging | $1,033.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,468.91 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $3,382.32 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $362.33 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $331.97 | 2024 | Farxiga |
| Ardelyx, INC. | $254.00 | 2024-2025 | Ibsrela |
| Amgen INC. | $230.75 | 2024-2025 | Tavneos |
| Travere Therapeutics, INC. | $206.66 | 2024-2025 | |
| Akebia Therapeutics INC | $163.93 | 2024-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $149.74 | 2024-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $114.30 | 2025 | Ozempic |
| Lilly USA, LLC | $101.40 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $61.17 | 2024-2025 | |
| Vifor Pharma, INC. | $39.68 | 2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $38.33 | 2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $32.77 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $24.71 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.43 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $15.64 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.